Announced details
Private-pay aging-care medical services, monitoring before and after interventions and supplement intake, and health management at clinics
Entered into an agreement to jointly roll out the NAD+ Test. 株式会社Rhelixa will provide the test to partner clinics, while we will handle the contracted testing and analysis. No capital or personnel relationship was stated.
Head office: 5F KDX Ginza East Building, 3-7-2 Irifune, Chuo-ku, Tokyo; Representative Director and President: Nakaki Ryu (仲木 竜). Contract omics analysis and consulting; development and operation of cloud services supporting biomedical research; and research and development and service provision related to anti-aging.
The impact on our results is expected to be immaterial.
The company does not address Contract Value / Offering price.
The Business Research Company, Longevity Clinic Global Market Report 2026
| Item | Details |
|---|---|
| Names of Products / Services Covered | NAD+ Test, Blood NAD+ High-Sensitivity Quantitative Analysis Service, Epigenetic Clock® Test |
| Counterparty | 株式会社Rhelixa |
| Counterparty overview | Head office: 5F KDX Ginza East Building, 3-7-2 Irifune, Chuo-ku, Tokyo; Representative Director and President: Nakaki Ryu (仲木 竜). Contract omics analysis and consulting; development and operation of cloud services supporting biomedical research; and research and development and service provision related to anti-aging. |
| Relationship with the Company | Entered into an agreement to jointly roll out the NAD+ Test. 株式会社Rhelixa will provide the test to partner clinics, while we will handle the contracted testing and analysis. No capital or personnel relationship was stated. |
| Contract Date | 7 August 2026 (announced as having entered into the agreement; the agreement date itself was not specified) |
| Launch date | To be determined (the start date of the business will be announced once decided) |
| Applicable area | Private-pay aging-care medical services, monitoring before and after interventions and supplement intake, and health management at clinics |
| Impact on Business Performance | The impact on our results is expected to be immaterial. |
| Source | The Business Research Company, Longevity Clinic Global Market Report 2026 |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand opportunities to introduce the "NAD+ Test" through 株式会社Rhelixa's nationwide clinic network and add new value to 株式会社Rhelixa's existing testing services through post-intervention monitoring.